Explore

TrendlineTrendline
QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform

QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform

QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform
TrendlineTrendline
Pierre Fabre and XtalPi Partner on AI-Driven Drug Discovery for Challenging Targets

Pierre Fabre and XtalPi Partner on AI-Driven Drug Discovery for Challenging Targets

Pierre Fabre and XtalPi Partner on AI-Driven Drug Discovery for Challenging Targets
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
TrendlineTrendline
AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development

AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development

AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development
Rapid ReadRapid Read
Scientists Discover Ancient Peptide with Enhanced Antibacterial Properties Using AI

Scientists Discover Ancient Peptide with Enhanced Antibacterial Properties Using AI

Scientists have utilized artificial intelligence (AI) and an evolutionary approach to uncover an ancient version of the protein lactoferrin, found in tears and breast milk, that possesses enhanced antibacterial properties. This protein, which emerged 160 million years ago, evolved from an ancestral gene called transferrin. Researchers, including Matthew F. Barber, PhD, associate professor of biology at the University of Oregon, reconstructed amino acid sequences from early lactoferrin and used AI program AlphaFold to predict structural evolution. They identified a highly positive charge on the surface of lactoferrin's ancestors, indicating its antibacterial function evolved after separating from transferrin. Notably, a specific amino acid substitution (arginine instead of glutamine) in non-human great apes' lactoferricin, a peptide derived from lactoferrin, significantly improved its antimicrobial activity against bacteria like Staphylococcus aureus. By engineering this substitution into human lactoferrici...
TrendlineTrendline
Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal
Rapid ReadRapid Read
mRNA COVID-19 Vaccines Show Unexpected Benefits in Cancer Treatment and Prevention

mRNA COVID-19 Vaccines Show Unexpected Benefits in Cancer Treatment and Prevention

Recent scientific findings indicate that mRNA COVID-19 vaccines may offer unexpected benefits beyond their primary role in preventing viral infection. Researchers have discovered that receiving an mRNA COVID shot can enhance the effectiveness of certain cancer therapies, leading to improved three-year survival rates for patients. This breakthrough has spurred pharmaceutical companies to explore and develop personalized cancer vaccines utilizing mRNA technology. These new vaccines aim to target individual patients' tumors, representing a significant advancement in oncology. This development highlights how scientific innovations, even when focused on one area, can yield unforeseen positive outcomes in other critical public health domains. The initial success in improving cancer therapy efficacy suggests a broader potential for mRNA technology in medical treatments.
TrendlineTrendline
AI for Drug Development and Discovery Market Projected to Reach $18.1 Billion by 2032

AI for Drug Development and Discovery Market Projected to Reach $18.1 Billion by 2032

AI for Drug Development and Discovery Market Projected to Reach $18.1 Billion by 2032
Rapid ReadRapid Read
University of Pittsburgh Professor Develops AI Framework for Drug Discovery

University of Pittsburgh Professor Develops AI Framework for Drug Discovery

Junmei Wang, a professor of pharmaceutical sciences at the University of Pittsburgh, has developed a new generative AI framework called Full-Spectrum Generative Lead Discovery (FSGLD). This framework, detailed in a paper published in the journal Science Advances on October 28, utilizes generative AI to screen existing compounds for potential therapeutic applications. Unlike traditional AI methods that often focus on generating new, potentially unsynthesizable molecules, FSGLD identifies real, existing compounds that can bind to target receptors. The system employs a general adversarial network (GAN) called DRUG-GAN, which learns to generate molecular fingerprints. These AI-generated patterns then guide researchers in searching chemical databases for existing molecules with similar characteristics. Wang's lab successfully used this method to screen for compounds linked to G protein-coupled receptors (GPCRs) and protein kinase, two commonly targeted drug receptors, identifying novel compounds that effectivel...
TrendlineTrendline
3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification
Rapid ReadRapid Read
Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

A personalized mRNA cancer vaccine, developed by Merck and Moderna, has demonstrated a 42% reduction in the risk of melanoma recurrence or death when combined with the immunotherapy drug Keytruda, compared to Keytruda alone. This experimental treatment, known as intismeran autogene, is a therapeutic vaccine tailored for individual patients with an existing cancer diagnosis. It functions by analyzing a tumor sample to identify genetic mutations that produce abnormal proteins (neoantigens) and then creating an mRNA treatment to stimulate an immune response against these specific cancer cell characteristics. The Phase 3 INTerpath-001 clinical trial involved over 1,100 high-risk melanoma patients whose tumors had been surgically removed. After a median follow-up of 24.6 months, the combination therapy also reduced the relative risk of cancer spreading to distant parts of the body or death by 38%. The detailed findings were announced on October 22, 2026, as part of the European Society for Medical Oncology (ESM...
Rapid ReadRapid Read
Gates Foundation Awards £2 Million Grant to PhaSER Biomedical for Drug Development Acceleration

Gates Foundation Awards £2 Million Grant to PhaSER Biomedical for Drug Development Acceleration

PhaSER Biomedical, a biotech startup, has secured a £2 million grant from the Bill & Melinda Gates Foundation. This two-year renewal funding aims to advance drug discovery for neglected diseases by providing humanized mouse models. The grant will expand access to PhaSER’s 8HUM platform and related translational modeling, which are designed to improve preclinical prediction and reduce species-related failures in drug development. The 8HUM transgenic mouse models are engineered to mimic human drug-metabolizing pathways, offering more human-relevant pharmacokinetic and safety signals earlier in the development process. This is particularly crucial for diseases like tuberculosis, malaria, schistosomiasis, and Chagas disease, which often receive limited commercial investment. The funding also supports collaborative research efforts with global health researchers and the University of Dundee's Drug Discovery Unit.